This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (21)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Diabetes Mellitus  • Hypertension  • Review  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Hoong Sern Lim, MRCP; Robert J. MacFadyen, MD, PhD, FRCP; Gregory Y. H. Lip, MD, FRCP

Arch Intern Med. 2004;164:1737-1748.

With diabetes mellitus reaching epidemic proportions, mainly secondary to obesity, the impact of cardiovascular disease due to this combination makes it a dominant public health problem during the first quarter of the 21st century. The complex interaction that results in diabetic heart disease is created by overlapping mechanisms. There is a propensity to develop premature, diffuse atherosclerotic coronary disease, which is associated with adverse short- and long-term morbidity and mortality. There are structural and functional abnormalities of the microvasculature, autonomic dysfunction, and intrinsic failure of myocardial contraction (so-called diabetic cardiomyopathy). These changes are amplified by arterial hypertension and kidney disease. In this review, we consider the role of the renin-angiotensin-aldosterone system and how it is a crucial driver of most of the pathophysiologic mechanisms behind diabetic heart disease and why in the past 5 years blocking this system in diabetic patients has emerged as a critical therapeutic intervention.

From the University Department of Medicine, City Hospital, Birmingham, England. Drs Lim and Lip are investigators in the ADVANCE trial, a large randomized trial of diabetic vascular outcomes supported by SERVIER Laboratories, and Drs MacFadyen and Lip have received funding for research, educational symposia, and lecturing from different manufacturers of drugs used for the treatment of hypertension, heart failure, and diabetes.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Captopril Normalizes Insulin Signaling and Insulin-Regulated Substrate Metabolism in Obese (ob/ob) Mouse Hearts
Tabbi-Anneni et al.
Endocrinology 2008;149:4043-4050.
ABSTRACT | FULL TEXT  

Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes
de Cavanagh et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H456-H465.
ABSTRACT | FULL TEXT  

A propensity-matched study of the effect of diabetes on the natural history of heart failure: variations by sex and age
Ahmed et al.
Heart 2007;93:1584-1590.
ABSTRACT | FULL TEXT  

A Thrombospondin-1 Antagonist of Transforming Growth Factor-{beta} Activation Blocks Cardiomyopathy in Rats with Diabetes and Elevated Angiotensin II
Belmadani et al.
Am. J. Pathol. 2007;171:777-789.
ABSTRACT | FULL TEXT  

Polymorphisms of the Renin-Angiotensin System Genes Predict Progression of Subclinical Coronary Atherosclerosis
Kretowski et al.
Diabetes 2007;56:863-871.
ABSTRACT | FULL TEXT  

Role of Aldose Reductase and Oxidative Damage in Diabetes and the Consequent Potential for Therapeutic Options
Srivastava et al.
Endocr. Rev. 2005;26:380-392.
ABSTRACT | FULL TEXT